[3H metyrapol and 4-[131I]iodometomidate label overlapping, but not identical, binding sites on rat adrenal membranes

Molecular Pharmaceutics

Volumn 10, Issue 3, 2013, Pages 1119-1130

  Berger, Michael L ^b   Hammerschmidt, Friedrich ^c   Qian, Renzhe ^c   Hahner, Stefanie ^d   Schirbel, Andreas ^d   Stichelberger, Martina ^a,e   Schibli, Roger ^e   Yu, Jie ^a,f   Arion, Vladimir B ^c   Woschek, Anna ^c   Öhler, Elisabeth ^c   Zolle, Ilse M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e PAUL SCHERRER INSTITUTE   (Switzerland)

^f PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

11 hydroxylase; etomidate; metyrapone; radioligand binding; rat adrenals

Indexed keywords

IODOMETOMIDATE I 131; METYRAPOL H 3; METYRAPONE; RADIOLIGAND; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BINDING SITE; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 84874640771     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3006227     Document Type: Article

References (46)

1. Omura, T. Mitochondrial P450s Chem.-Biol. Interact. 2006, 163, 86-93
2. Belelli, D.; Lambert, J. J.; Peters, J. A.; Wafford, K.; Whiting, P. J. The interaction of the general anesthetic etomidate with the γ-aminobutyric acid type A receptor is influenced by a single amino acid Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 11031-11036
3. A receptor: Comparison with binding to 11 β -hydroxylase Bioorg. Med. Chem. Lett. 2009, 19, 4284-4287
4. 11C-metomidate J. Nucl. Med. 2000, 41, 275-282
5. 123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes J. Clin. Endocrinol. Metab. 2008, 93, 2358-2365
6. 3H]metyrapol, an inhibitor of the 11 β -hydroxylation reaction Biochemistry 1974, 13, 2201-2209
7. 3H]Metyrapol as a tool for studies of interactions of deoxycorticosterone with adrenal cortex mitochondria FEBS Lett. 1972, 26, 193-196
8. Zolle, I. M.; Berger, M. L.; Hammerschmidt, F.; Hahner, S.; Schirbel, A.; Peric Simov, B. New selective inhibitors of steroid 11 β -hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues J. Med. Chem. 2008, 51, 2244-2253
9. Fallo, F.; Pezzi, V.; Barzon, L.; Mulatero, P.; Veglio, F.; Sonino, N.; Mathis, J. M. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas Eur. J. Endocrinol. 2002, 147, 795-802
10. Ye, P.; Kenyon, C. J.; MacKenzie, S. M.; Jong, A. S.; Miller, C.; Gray, G. A.; Wallace, A.; Ryding, A. S.; Mullins, J. J.; McBride, M. W.; Graham, D.; Fraser, R.; Connell, J. M. C.; Davies, E. The aldosterone synthase (CYP11B2) and 11 β -hydroxylase (CYP11B1) genes are not expressed in the rat heart Endocrinology 2005, 146, 5287-5293
11. 2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line Toxicol. In Vitro 2002, 16, 113-121
12. Tobes, M. C.; Hays, S. J.; Gildersleeve, D. L.; Wieland, D. M.; Beierwaltes, W. H. Adrenal cortical 11 β -hydroxylase and side-chain cleavage enzymes. Requirement for the A- or B-pyridyl ring in metyrapone for inhibition J. Steroid Biochem. 1985, 22, 103-110
13. Turpeinen, M.; Nieminen, R.; Juntunen, T.; Taavitsainen, P.; Raunio, H.; Pelkonen, O. Selective inhibition of CYP2B6-catalized bupropion hydroxylation in human liver microsomes in vitro Drug Metab. Dispos. 2004, 32, 626-631
14. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues Curr. Drug Metabol. 2008, 9, 129-143
15. Morton, T. H. Neutral products from gas phase rearrangements of simple carbocations Adv. Gas-Phase Ion Chem. 2001, 4, 213-256
16. 123/131I]Iodometomidate as a radioligand for functional diagnosis of adrenal disease: synthesis, structural requirements and biodistribution Radiochim. Acta 2004, 92, 297-303
17. Robien, W.; Zolle, I. Synthesis of radioiodinated metyrapone-a potential adrenal imaging agent Int. J. Appl. Radiat. Isot. 1983, 34, 907-914
18. Hays, S.; Tobes, M. C.; Gildersleeve, D. L.; Wieland, D. M.; Beierwaltes, W. H. Structure-activity relationship study of the inhibition of adrenal cortical 11 β -hydroxylase by new metyrapone analogues J. Med. Chem. 1984, 27, 15-19
19. Zolle, I.; Yu, J.; Robien, W.; Woloszczuk, W.; Höfer, R. Biochemical evaluation of metyrapone derivatives-inhibition kinetics and affinity studies J. Labelled Compd. Radiopharm. 1991, 30, 420-422
20. Zbiral, E.; Brandstetter, H. H.; Schreiner, E. P. Strukturelle Abwandlungen an N -Acetylneuraminsäuren, 8 [1] Synthese von 7-, 8-, 9-Desoxy- und 4,7-Didesoxyneuraminsäure Monatsh. Chem. 1988, 119, 127-141
21. 3SiH: Twenty Years After Its Discovery as a Radical-Based Reducing Agent Chem.-Eur. J. 2008, 14, 2310-2320
22. Howe, R.; Moore, R. H. Microbiological Reduction of 2-Methyl-1,2-di-3- pyridyl-1-propanone (Metyrapone) J. Med. Chem. 1971, 14, 287-288
23. Cassiano, N. M.; Cass, Q. B.; Degani, A. L. G.; Wainer, I. W. Determination of the Plasma Levels of Metyrapone and Its Enantiomeric Metyrapol Metabolites by Direct Plasma Injection and Multidimensional Achiral-Chiral Chromatography Chirality 2002, 14, 731-735
24. Nagamine, S.; Horisaka, E.; Fukuyama, Y.; Maetani, K.; Matsuzawa, R.; Iwakawa, S.; Asada, S. Stereoselective reductive metabolism of metyrapone and inhibitory activity of metyrapone metabolites, metyrapol enantiomers, on steroid 11 β -hydroxylase in the rat Biol. Pharm. Bull. 1997, 20, 188-192
25. Rigel, D. F.; Fu, F.; Beil, M.; Hu, C.-W.; Liang, G.; Jeng, A. Y. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11 β -hydroxylase inhibitor metyrapone J. Pharmacol. Exp. Ther. 2010, 334, 232-243
26. Noe, C. R.; Knollmüller, M.; Oberhauser, B.; Steinhauser, G.; Wagner, E. Eine Methode zur Bestimmung der Absolutkonfiguration chiraler α -hydroxysubstituierter Nitrile, Alkine und Aldehyde Chem. Ber. 1986, 119, 729-743
27. Seco, J. M.; Quiñoá, E.; Riguera, R. The Assignment of Absolute Configuration by NMR Chem. Rev. 2004, 104, 17-117
28. Bélai, I.; Matolcsy, G.; Farnsworth, D. E.; Feyereisen, R. Inhibition of insect cytochrome P-450 by some metyrapone analogues and compounds containing a cyclopropylamine moiety and their evaluation as inhibitors of juvenile hormone biosynthesis Pestic. Sci. 1988, 24, 205-219
29. Hammerschmidt, F.; Peric Simov, B.; Schmidt, S.; Schneider, S.; Zolle, I. Chemoenzymatic synthesis of stannylated metomidate as a precursor for electrophilic radiohalogenations-regioselective alkylation of methyl 1 H -imidazole-5-carboxylate Monatsh. Chem. 2005, 136, 229-239
30. Corelli, F.; Summa, V.; Brogi, A.; Monteagudo, E.; Botta, M. Chiral Azole Derivatives. 2. Synthesis of Enantiomerically Pure 1-Alkylimidazoles J. Org. Chem. 1995, 60, 2008-2015
31. 99mTc(I)-tricarbonyl-(R)-bipyridyl-MTO-conjugate. In Trends in Radiopharmaceuticals (Istr-2005); IAEA: 2007; pp 383-393.
32. 99mTc(I)-tricarbonyl complex Monatsh. Chem. 2010, 141, 437-443
33. Yu, J. Evaluation of metyrapone derivatives for functional imaging of the adrenals. Thesis, Technical University Vienna, 1993.
34. Hulme, E. C. Centrifugation binding assays. In Receptor-Ligand Interactions. A Practical Approach; Hulme, E. C., Ed.; Oxford University Press: 1992; pp 235-246.
35. Zolle, I., Ed. Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine; Springer: 2006.
36. 99mTc]metomidate as the tricarbonyl-conjugate. J. Labelled Compd. Radiopharm. 2001, 44/1 (Suppl.).
37. Roumen, L.; Sanders, M. P. A.; Pieterse, K.; Hilbers, P. A. J.; Plate, R.; Custers, E.; de Gooyer, M.; Smits, J. F. M.; Beugels, I.; Emmen, J.; Ottenheijm, H. C. J.; Leysen, D.; Hermans, J. J. R. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics J. Comput.-Aided Mol. Des. 2007, 21, 455-71
38. Fassnacht, M.; Hahner, S.; Beuschlein, F.; Klink, A.; Reincke, M.; Allolio, B. New mechanisma of adrenostatic compounds in a human adrenocortical cancer cell line Eur. J. Clin. Invest. 2000, 30, 76-82
39. Belkina, N. V.; Lisurek, M.; Ivanov, A. S.; Bernhardt, R. Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2 J. Inorg. Biochem. 2001, 87, 197-207
40. Mathre, D. J.; Thompson, A. S.; Douglas, A. W.; Hoogsteen, K.; Carroll, J. D.; Corley, E. G.; Grabowski, E. J. J. A practical process for the preparation of tetrahydro-1-methyl-3,3-diphenyl-1 H,3 H -pyrrolo[1,2-c][1,3,2] oxazaborole-borane. A highly enantioselective stoichiometric and catalytic reducing agent J. Org. Chem. 1993, 58, 2880-2888
41. Laumen, K.; Breitgoff, D.; Schneider, M. P. A highly selective ester hydrolyse from Pseudomonas sp. for the enzymatic preparation of enantiomerically pure secondary alcohols; chiral auxiliaries in organic synthesis J. Chem. Soc., Chem. Commun. 1988, 1459-1461
42. Zolle, I.; Woloszczuk, W.; Höfer, R. Synthesis and in vitro evaluation of metyrapone derivatives as potential inhibitors of 11 β -hydroxylase activity. In Radiopharmaceuticals and Labeled Compounds; IAEA: Vienna, 1985; pp 337-342.
43. SAINT-Plus, version 7.06a and APEX2; Bruker-Nonius AXS Inc.: Madison, WI, 2004.
44. Sheldrick, G. M. Phase annealing in SHELX-90: direct methods for larger structures Acta Crystallogr. 1990, A46, 467-473
45. Sheldrick, G. M. A short history of SHELX Acta Crystallogr. 2008, A64, 112-122
46. Burnett, M. N.; Johnson, G. K. ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal Structure Illustrations, Oak Ridge National Laboratory Report ORNL-6895, Oak Ridge, TN, 1996.